Heavy Metal Therapy: Realising the potential of ²¹²Pb targeted alpha therapies

Radionuclide therapies are sparking a revolution in nuclear medicine and are changing the way we treat cancer. But though there’s been success using lutetium-177, these therapies are not curative, and patients eventually relapse. Targeted alpha therapies are seen as the next evolution of radionuclide therapy – compared to they are more potent at killing cancel cells, but also more targeted, resulting in less unwanted damage.